CheckMate 7A8 study (Table 3) evaluated neoadjuvant treatment based on palbociclib with anastrozole (a non-steroidal aromatase inhibitor) and nivolumab in patients with ER+ breast cancer. Here, CYP19A1 is linked to breast carcinoma.